Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial

• Published in: Journal of diabetes investigation 2019-05, Vol.10 (3), p.699-705
• Main Authors: Takase, Takahiro, Nakamura, Akinobu, Yamamoto, Chiho, Nomoto, Hiroshi, Miya, Aika, Dannoura, Midori, Cho, Kyu Yong, Kurihara, Yoshio, Manda, Naoki, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
• Format: Article
• Language: English
• Subjects: Agonists; Antidiabetics; Biomarkers - analysis; Blood Glucose - analysis; Body mass; Clinical Trial; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Dulaglutide; Female; Follow-Up Studies; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptides - analogs & derivatives; Glucagon-Like Peptides - therapeutic use; Glycated Hemoglobin A - analysis; Hemoglobin; Humans; Hypoglycemia; Hypoglycemia - prevention & control; Hypoglycemic Agents - therapeutic use; Immunoglobulin Fc Fragments - therapeutic use; Insulin; Liraglutide - therapeutic use; Male; Middle Aged; Patient satisfaction; Personal Satisfaction; Pharmaceuticals; Prognosis; Prospective Studies; Public speaking; Quality of Life; Questionnaires; Recombinant Fusion Proteins - therapeutic use; Research funding; Studies; Treatment satisfaction; Type 2 diabetes
• ISSN: 2040-1116; 2040-1124
• DOI: 10.1111/jdi.12906

Aims/Introduction We compared treatment satisfaction in type 2 diabetes patients taking daily and weekly glucagon‐like peptide‐1 receptor agonists. Materials and Methods The study was a 12‐week, multicenter, open‐label, prospective, randomized, parallel‐group comparison trial. The participants were Japanese patients with type 2 diabetes being administered with the glucagon‐like peptide‐1 receptor agonist, liraglutide, daily for >3 months. Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group). The primary outcome was the change in the Diabetes Treatment Satisfaction Questionnaire score from baseline to week 12 in the two groups. The secondary outcomes comprised changes in the Diabetes Therapy‐Related Quality of Life score, body mass and glycemic control. Results A total of 33 participants were initially enrolled in the trial, and 31 participants completed the protocol. The change in the Diabetes Treatment Satisfaction Questionnaire score in the Dula group was significantly greater than that in the Lira group (+0.1 ± 4.7 in the Lira group vs +4.9 ± 5.2 in the Dula group; P = 0.013). The change in Diabetes Therapy‐Related Quality of Life score in the Dula group was significantly greater than that in the Lira group (−3.7 ± 6.9 vs +8.9 ± 15.1; P = 0.007). There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin. Conclusions Weekly administration of dulaglutide was superior to liraglutide with regard to treatment satisfaction in patients with type 2 diabetes, in the absence of any negative effect on glycemic control. The study was a 12‐week, multicenter, open‐label, prospective, randomized, parallel‐group comparison trial to evaluate treatment satisfaction for two types of glucagon‐like peptide‐1 receptor agonists. The scores of the treatment satisfaction questionnaires by switching to dulaglutide once weekly was improved than those in continuing liraglutide once daily. Weekly administration of dulaglutide was superior to liraglutide with regard to treatment satisfaction in patients with type 2 diabetes, without having any effect on glycemic control.